FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

ORCHIDPHAR Share Price Discussion

Orchid Pharma Ltd.
Sector: Pharmaceuticals and health care
... Read more
ORCHIDPHAR Long Term Analysts Rating
0/5 (0 Ratings)
ORCHIDPHAR Share Price *
0 +0 (0%)
* (quote may be delayed)

Find answers to all your questions on live ORCHIDPHAR message board: Is ORCHIDPHAR buy or sell? Should I buy ORCHIDPHAR shares? Why are ORCHIDPHAR shares falling? Should I invest in ORCHIDPHAR stock?


ORCHIDPHAR Discussion Forum

@newsbot • Reputation: 1,933
Orchid Pharma Standalone June 2019 Net Sales at Rs 135.77 crore, up 3.92% Y-o-Y
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 1,933
Orchid Pharma Consolidated June 2019 Net Sales at Rs 135.42 crore, up 0% Y-o-Y
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
  • ORCHIDPHAR - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization47.42
    Enterprise Value1,843.25
    Price to Earnings12.64
    Price to Book Value1.94
    Return on Capital Employed-0.02
    Return on Equity0.53
    Face Value10
    Dividend YieldNA
  • ORCHIDPHAR - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue644755.36-0.15
    Operating Profit22-80.62-1.27
    Profit Before Tax-401-531.68-0.25
    Net Income-355-483.63-0.27
  • ORCHIDPHAR - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds-755-6740.12
    Total Liabilities3,7483,885-0.04
    Total Assets2,9933,211-0.07
  • ORCHIDPHAR - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity6317.68-0.98
    Cash from Investing Activity-28-8.622.25
    Cash from Financing Activity33-366.12-1.09
    Net Cash Flow11-57.07-1.19
  • ORCHIDPHAR - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-0.11-0.14
    Return on Equity0.531.83
    Return on Capital Employed-0.02-0.07
  • ORCHIDPHAR - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.6
    3 Year CAGR Growth in Operating Profit-2.09
    3 Year CAGR Growth in EBIDTA-1.28
    3 Year CAGR Growth in Net Income0.09
    3 Yr CAGR Growth - Diluted EPS0.28
  • ORCHIDPHAR - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.55
    5 Year CAGR Growth in Operating Profit-1.23
    5 Year CAGR Growth in EBIDTA-1.15
    5 Year CAGR Growth in Net Income-4.03
    3 Yr CAGR Growth - Diluted EPS-3.4
  • ORCHIDPHAR - Recent News

    keyboard_arrow_down
    NewsBot
    Aug 13 8:43 PM
    Orchid Pharma Standalone June 2019 Net Sales at Rs 135.77 crore, up 3.92% Y-o-Y
    moneycontrol.com
    NewsBot
    Aug 13 7:18 PM
    Orchid Pharma Consolidated June 2019 Net Sales at Rs 135.42 crore, up 0% Y-o-Y
    moneycontrol.com
    NewsBot
    Jun 26 10:23 PM
    NewsBot
    Jun 26 5:43 PM
    NewsBot
    Jun 6 12:48 PM
    NewsBot
    Jun 4 1:08 PM
    NewsBot
    Jun 3 12:58 AM
    NewsBot
    May 27 12:38 AM
    NewsBot
    May 15 3:13 PM
  • ORCHIDPHAR - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Dr. Reddy's Laboratories Ltd. Sector...
    Piramal Enterprises Ltd. Sector: Phar...
    Glenmark Pharmaceuticals Ltd. Sector...
    Divi's Laboratories Ltd. Sector: Pha...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.